Page 94 - 2018_11-Haematologica-web

A.C. Fassoni et al.
ized CML-study IV. Leukemia. 2015;29
(5):1123-1132.
25. Deininger MW, O'Brien SG, Ford JM,
Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21 (8):1637-1647.
26. La Rosee P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-posi- tive cell lines. Blood. 2004;103(1):208-215.
27. Radivoyevitch T, Hlatky L, Landaw J, Sachs RK. Quantitative modeling of chronic myeloid leukemia: insights from radiobiol- ogy. Blood. 2012;119(19):4363-4371.
28. Peng B, Lloyd P, Schran H. Clinical pharma- cokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-894.
29. Naqvi K, Jabbour E, Skinner J, et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diag- nosed chronic-phase chronic myeloid leukemia. Cancer. 2018;35(15):e18551.
30. Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermit- tent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138-5144.
34. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-
31. Hehlmann R, Lauseker M, Saussele S, et al. 522.
Assessment of imatinib as first-line treat- ment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determi- nants. Leukemia. 2017;31(11):2398-2406.
32. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054.
33. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multi- centre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
35. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
36. Glauche I, Horn M, Roeder I. Leukaemia stem cells: hit or miss? Br J Cancer. 2007;96(4):677-678.
37. Besse A, Lepoutre T, Bernard S. Long-term treatment effects in chronic myeloid leukemia. J. Math. Biol. 2017;75(3):733-758.
38. Werner B, Scott JG, Sottoriva A, Anderson AR, Traulsen A, Altrock PM. The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient- Specific Treatment Trajectories. Cancer Res. 2016;76(7):1705-1713.
1834
haematologica | 2018; 103(11)